Enzymotec Ltd. (NASDAQ:ENZY) Given $7.75 Average Price Target by Analysts
Shares of Enzymotec Ltd. (NASDAQ:ENZY) have earned an average broker rating score of 2.67 (Hold) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and one has given a strong buy recommendation to the company.
Analysts have set a one year consensus price target of $7.75 for the company and are anticipating that the company will post $0.04 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Enzymotec an industry rank of 177 out of 265 based on the ratings given to its competitors.
Several equities analysts have recently commented on ENZY shares. Jefferies Group reiterated a “hold” rating on shares of Enzymotec in a research report on Thursday, August 4th. Zacks Investment Research lowered Enzymotec from a “buy” rating to a “hold” rating in a research report on Friday, July 22nd.
Several institutional investors have recently made changes to their positions in the stock. Algert Global LLC bought a new position in Enzymotec during the first quarter valued at about $190,000. BlackRock Institutional Trust Company N.A. raised its position in Enzymotec by 13.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 19,015 shares of the company’s stock valued at $172,000 after buying an additional 2,318 shares during the last quarter. Geode Capital Management LLC bought a new position in Enzymotec during the first quarter valued at about $114,000. Menta Capital LLC raised its position in Enzymotec by 49.6% in the first quarter. Menta Capital LLC now owns 43,126 shares of the company’s stock valued at $389,000 after buying an additional 14,295 shares during the last quarter. Finally, Icon Advisers Inc. Co. bought a new position in Enzymotec during the first quarter valued at about $152,000. Hedge funds and other institutional investors own 36.20% of the company’s stock.
Enzymotec (NASDAQ:ENZY) opened at 7.12 on Wednesday. The firm has a market capitalization of $161.76 million, a price-to-earnings ratio of 37.47 and a beta of 1.27. The firm has a 50-day moving average price of $7.32 and a 200 day moving average price of $8.14. Enzymotec has a 52 week low of $6.60 and a 52 week high of $10.32.
Enzymotec (NASDAQ:ENZY) last released its quarterly earnings results on Tuesday, August 9th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.04. Enzymotec had a net margin of 8.37% and a return on equity of 3.12%. The business earned $15 million during the quarter, compared to analysts’ expectations of $14.90 million. During the same period in the previous year, the business earned $0.11 EPS. The business’s revenue was down 12.7% on a year-over-year basis. On average, equities research analysts forecast that Enzymotec will post $0.27 earnings per share for the current fiscal year.
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.